Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.

Lancet (London, England) - 26 Jun 1999

Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, Montagne N, Boucher C A, Schapiro J M, Dellamonica P

Abstract excerpt

BACKGROUND: Growing evidence has linked HIV-1 resistance mutations and drug failure. The use of genotypic-resistance analysis to assist therapeutic decision-making in patients failing therapy has not been investigated. We assessed the virological and immunological impact of genotypic-resistance testing. METHODS: We did a prospective, open, randomised, controlled study of HIV-1-infected patients in whom...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acquired Immunodeficiency Syndrome
Share to CD4 Lymphocyte Count

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Contraindications

Share to Endopeptidases

Share to HIV Reverse Transcriptase

Share to Pilot Projects

Share to Protease Inhibitors

Share to Reverse Transcriptase Inhibitors

Source

Identifiers

PMID: 10392984
DOI: 10.1016/s0140-6736(98)12291-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.PMID 10392984Read ↗

Genotypic resistance testing in routine clinical care.Semantic proximity Read ↗

HIV-1 drug resistance assays in clinical management.Semantic proximity Read ↗

Resistance testing debate: does it make the grade?Semantic proximity Read ↗

Development and performance of conventional HIV-1 phenotyping (Antivirogram®) and genotype-based calculated phenotyping assay (virco®TYPE HIV-1) on protease and reverse transcriptase genes to evaluate drug resistance.Semantic proximity Read ↗

International perspectives on antiretroviral resistance. Clinical utility of resistance testing: retrospective and prospective data supporting use and current recommendations.Semantic proximity Read ↗

Detection of HIV-1 antiretroviral resistance from patients with persistently low but detectable viraemia.Semantic proximity Read ↗

Interpreting resistance data for HIV-1 therapy management--know the limitations.Semantic proximity Read ↗

Human immunodeficiency virus type 1 pharmacogenomics in clinical practice: relevance of HIV-1 drug resistance testing (Part 1).Semantic proximity Read ↗

Antiretroviral resistance in clinical practice.Semantic proximity Read ↗

Human immunodeficiency virus type 1 pharmacogenomics in clinical practice: relevance of HIV-1 drug resistance testing (Part 2).Semantic proximity Read ↗

Reliability and Clinical Relevance of the HIV-1 Drug Resistance Test in Patients With Low Viremia LevelsSemantic proximity Read ↗

Performance of an in-house genotypic antiretroviral resistance assay in patients pretreated with multiple human immunodeficiency virus type 1 protease and reverse transcriptase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.